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Brucellosis is a serious zoonosis occurring mainly in developing countries, and its
diagnosis is largely dependent on serologic detection and bacterial culture. In this
study, we developed the murine monoclonal antibodies (mAbs) against a conserved
and major outer membrane protein 25 (Omp25) of Brucella species (B. spp.) for use in
clinical diagnosis. The mAbs to Omp25 were produced by hybridoma technique, which
were utilized for developing various immunoassays for detection of Brucellae, including
Western blot (WB), enzyme-linked immunosorbent assay (ELISA), immunochemical
staining (ICS), immunofluorescence staining (IFS), and flow cytometry assay (FCM). A
number of five mAbs (2B10, 4A12, 4F10, 6C12, and 8F3) specific to Omp25 were
selected, including 2 IgG1, 2 IgG2a, and 1 IgG2b. Among them, mAbs 6C12, 8F3, and
4A12 reacted highly with B. melitensis (M5-90), B. abortus (S19, 104M, and 2308), and
B. suis strain (S2). No cross-reactivity with Yersinia enterocolitica O:9, Salmonella spp.,
and Escherichia coli was found. By mapping Omp25 epitopes, mAb 6C12 was found as
reacting with a semi-conformational epitope, and mAbs 4A12 and 8F3 as recognizing a
different linear epitope, respectively. The paired mAbs were tested for detecting Brucella
species, suggesting that 8F3 was suitable for solid phase capture and 6C12 or 4A12 was
suitable for conjugation with HRP for detection of Brucella Omp25 in ELISA. The FCM
was established by mAb 6C12 for detecting intracellular Brucellae-infected peripheral
blood mononuclear cells (PBMCs) from brucellosis patients. In conclusion, mAbs against
Omp25 are precious reagents for detection of Brucellae in clinical samples with various
immunoassays. mAb 6C12-based FCM could be potentially used for the monitoring of
therapeutic efficacy for brucellosis in clinical practice.
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INTRODUCTION
Brucellosis is a severe zoonotic disease distributed worldwide,
especially in the developing world (Wang et al., 2015). Sheep,
goats, cattle, and pigs infected by Brucella species are the
main sources of human brucellosis (Ducrotoy et al., 2018).
In the past 10 years, human brucellosis has increased rapidly
in China. There were 37,947 new cases of human brucellosis
nationwide (morbidity 2.7318/100,000) in 2018 as reported
by the Chinese CDC (http://www.nhc.gov.cn/jkj/s3578/201904/
050427ff32704a5db64f4ae1f6d57c6c.shtml). New cases of human
brucellosis were reported in non-endemic areas such as the
Guangdong province (Chen et al., 2014), which is located in the
south of China and far away from the high prevalence areas such
as Inner Mongolia, Heilongjiang, Xinjiang, and Shanxi in the
north or west of China (Wang et al., 2015).
At present, diagnosis of brucellosis mainly depends on
serological methods used to detect antibodies against Brucellae
in infected animals or humans (Araj, 2010). Diagnosing
brucellosis by means of Brucellae cultures themselves can take
at least 10 days. Once a Brucella infection becomes chronic,
patients are likely to carry the bacteria for their whole lives.
Anti-Brucellae methods are the most important approach for
treatment of brucellosis. However, currently there are no
rapid, simple, and quantitative methods for the evaluation of
therapeutic efficacy of brucellosis during hospitalization. Brucella
outer membrane proteins (Omps) are excellent candidates for
the serologic diagnosis of a Brucella infection and potential
antigens for recombinant subunit vaccines against brucellosis
(Ahmed et al., 2015; Yousefi et al., 2016). Omp25 is one
major Omps of the Brucella species and is considered to
be closely related to virulence of Brucellae (Salhi et al.,
2003; Goel and Bhatnagar, 2012). Brucella species without
Omp25 survive for a shorter period of time than wild-
type strains in mice (Edmonds et al., 2001, 2002). As a
structural protein, Omp25 is highly conserved in various types
and subtypes of Brucellae and induces a strong immune
response (Cloeckaert et al., 2002; Goel et al., 2013; Ma et al.,
2015). Therefore, it might be a useful diagnostic target for
brucellosis. In a previous study, an antibody to Omp25 was
used to identify rough Brucella isolates by means of a latex
coagglutination test (Bowden et al., 1997). In this study, we
aimed to generate novel monoclonal antibodies (mAbs) to
Omp25 and to develop new immunoassays for diagnosis of
brucellosis or evaluation of therapeutic efficacy of brucellosis in
clinical practice.
MATERIALS AND METHODS
Bacterial Strains
Inactivated Brucella strains, including B. melitensis (M5-90),
B. abortus (S19, 104M and 2308), and B. suis (S2), were
provided from Shihezi University, Xinjiang, China. Yersinia
enterocolitica O:9, Salmonella spp., and Escherichia coli (ATCC
23922) were provided from the Department of Microbiology,
Southern Medical University (SMU), Guangzhou, China.
Recombinant Brucella Omps
Recombinant proteins of Omp31, Omp19, Omp16, and
periplasmic protein 26 (BP26) were produced from B. melitensis
strain in the laboratory (Qiu et al., 2012; He et al., 2016; Li et al.,
2017). Omp25 gene (642 bp) from B. melitensis M5-90 genomic
DNAwas cloned into the pET30a expression vector (Zhang et al.,
2014; Yousefi et al., 2016), and designated as pET30a-Omp25.
Recombinant Omp25 (rOmp25) was expressed as an inclusion
body in Escherichia coli (DH5α) by induction with 1mM IPTG.
The rOmp 25 extract was denatured by 8M urea and purified
by Ni-NTA Agarose (GE Healthcare, Milwaukee, Wisconsin,
USA), and then refolded by dialysis against 50mM Tris-HCl
buffer containing a declining gradient urea from 6, 4, 2, to 0M
(Qiu et al., 2012; Yousefi et al., 2016). Sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) was utilized
to analyze rOmp25 (Yousefi et al., 2016). The purified soluble
rOmp25 was used for mouse immunization and development of
serologic tests.
Mouse Immunization and Monoclonal
Antibody Production
BALB/c mice were obtained from the Animal Experimental
Center of Southern Medical University (SMU), Guangzhou,
China. BALB/c mice were immunized with purified rOmp25.
The hybridoma cells, secreting mAbs to rOmp25, were generated
and selected according to a previously reported method (Qiu
et al., 2012; Patra et al., 2014; Li et al., 2017). To prepare the
ascitis fluid, BALB/c mice sensitized by the liquid paraffin were
injected subcutaneously with 106/ml hybridoma cells. Themouse
ascites fluid was collected and purified by Recombinant Protein
G NUPharose Fast Flow, rProtein G NUPharose FF (Nuptec,
Hangzhou, China) (Divya et al., 2018).
All animal experimentations were approved by Southern
Medical University (SMU) Animal Care and Use Committee
(permit numbers: NFYY-2008-043 and NFYY-2010-076). All
mouse surgery was performed under anesthesia, and all efforts
were made to minimize suffering of animals.
mAb Isotyping
The isotype ofmAbs was determined by IsoQuick Strips (amouse
mAb isotyping kit, Sigma-Aldrich, St Louis, Missouri, USA).
Blood Samples From Patients and Blood
Donors
Plasma, or peripheral blood mononuclear cells (PBMCs), were
isolated from healthy blood donors in Guangzhou and Harbin
blood centers. Blood samples from brucellosis patients were
collected at the General Hospital of Agricultural Reclamation
Bureau, Harbin, Heilongjiang, China. All blood donor or patient
samples were confirmed for negativity or positivity to Brucella
infection by Standard Agglutination Test (SAT) and Polymerase
Chain Reaction (PCR) (Mohammadi and Golchin, 2018). The
PBMCs were prepared according to manufacturer’s instructions
(Ficoll Pague PLUS, GE Healthcare Life Sciences, USA).
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Peptides
Peptides spanning 213 amino acids of Omp25 were synthesized
as P1–P10 (Table S1) by a commercial company (Chinese
Yuantai Company, Nanjing, China). A peptide of Omp31 (EP24:
EYLYTDLGKRNLVDVD) was used as a negative control. The
purity of all peptides was more than 90% of total weight.
mAbs Titration and Affinity Measurement
The concentration of purified mAbs was determined by
NanoDrop 2000 (Thermo Fisher Scientific, USA) as 1.14 mg/ml
for 4F10, 2.1 mg/ml for 2B10, 7.4 mg/ml for 6C12, 3.8 mg/ml for
8F3, and 1.9 mg/ml for 4A12, respectively. The titer of mAbs was
measured by indirect ELISA (Qiu et al., 2012; Divya et al., 2018).
The Immuno MicroWell plate was coated with 5µg/ml rOmp25
in 0.1M carbonate buffer (CBS, pH 9.6) overnight at 4◦C and
blocked in 1% bovine serum albumin (BSA) for 1 h at 37◦C.
The purified mAbs as primary antibody were serially diluted
from 1:100 to 1:1,968,300, and then added to microwell plate for
1 h at 37◦C. ELISA plates were incubated for 1 h at 37◦C with
1:10,000 diluted goat anti-mouse IgG and IgM HRP-conjugate
antibodies (Rockland Immunochemicals, Inc, USA). The optical
densities (OD) of reactions were detected with Epoch Microplate
Spectophotometer (BioTek Instruments, Inc. Winooski, USA).
mAb titer was finally defined as the dilution fold at OD450 value
of 1 by indirect ELISA.
mAb’s relative affinity was determined according to reactivity
in different concentration of ammonium thiocyanate (NH4SCN)
solutions ranging between 0 and 4 M/L for 30min at room
temperature (Pullen et al., 1986; Macdonald et al., 1988). The
appropriate concentration of primary mAbs was determined on
the titration curve, which corresponded to the optical density
observed near the top of the curve’s linear portion (Macdonald
et al., 1988). All experiments were carried out in triplicate and
the mean of OD450 values obtained from three independent
experiments was used to calculate the relative affinity.
Lentivirus-Mediated Omp25 Expression in
Cells
The infectious recombinant lentivirus (LV-HAGE-Omp25)
mediated Omp25 expression in 293FT cell as described
previously, mimicking Brucella Omp25 antigen in the infected
mammalian cells (Zhang et al., 2012; Li et al., 2017).
Western Blot (WB)
The supernatant of sonicated proteins (SSPs) from B. melitensis
(M5-90), B. abortus (S19, 104M, and 2308), and B. suis (S2)
were considered as the native Omp25 lysates, which were
prepared by breaking Brucella spp. stains with ultrasonication
(Ultrasonic Apparatus XO-650, Xianou, Nanjing, China). The
native membrane protein extracts (NMPs) was prepared by
Membrane Protein Extraction Kit (Bestbio, China). The rOmp25
and native Omp25 were electrophoresed on SDS-PAGE and
transferred to Polyvinylidene Fluoride membranes (PVDF
membranes, Millipore, Billerica, Massachusetts, USA). The
blotted membrane was incubated in 1:1,000 diluted mAb for 2 h
at room temperature. The strip was washed in TBS containing
0.05% Tween R©20 (TBST) and incubated with 1:5,000 dilution
of goat anti-mouse IgG and IgM HRP-conjugate antibodies.
The blot was visualized by adding immuno-chemiluminescence
reagent (ECL,Millipore, Billerica, Massachusetts, USA). AnHCV
rNS3 mAb was used as unrelated negative control (Qiu et al.,
2012). The SSPs from E. coli (ATCC23922) strain was used as
negative control.
Enzyme-Linked Immunosorbent Assay
(ELISA)
In indirect ELISA, rOmp25 or native Omp25 was used as
a coating antigen. Purified mAbs were used as the primary
antibody at optimum working concentration. The microwell
plate was incubated with a 1:10,000 dilution of goat anti-
mouse IgG and IgM HRP-conjugate antibodies as reported
previously (Tiwari et al., 2013; Ahmed et al., 2015). In peptide-
ELISA, peptides P1–P10 were used to identify antigenic epitopes
recognized by each mAb (Qiu et al., 2012; Li et al., 2017).
The double-antibody sandwich ELISA (DAS-ELISA) was used to
detect Brucella Omp25 by cross-matching mAbs in pair with a
capture mAb coated on the microwell plate and a detection mAb
conjugated with HRP (Luo et al., 2012).
Immunofluorescent Staining (IFS)
293FT cells were transduced with recombinant lentivirus
expressing Omp25 (LV-HAGE-Omp25) at multiplicities of
infection (MOI = 5) for 8 h. The transduced 293FT cells were
detected by immunofluorescent staining (IFS) with Omp25
mAbs as same as with Omp31 or BP26 described previously (Li
et al., 2017). PBMCs were collected from two brucellosis patients
(Guangzhou Center for Disease Prevention and Control) and
were tested by IFS with mAb 6C12. PBMCs from a healthy blood
donor were used as the negative control.
Immunochemical Staining (ICS)
Intact Brucella were detected by using ICS (Li et al., 2017).
Briefly, after pretreatment with 3% H2O2 and washing with
PBS three times, the Brucella smears on the glass-slide reacted
with Omp25 mAbs and saturated with goat anti-mouse IgG and
IgM HRP conjugate (Rockland Immunochemicals, Inc, USA).
Bacteria were visualized with diaminobenzidine (DAB) substrate
for color development.
Flow Cytometry Assay (FCM)
To explore the capacity of mAb to recognize intracellular
Brucellae in PBMCs of patients with brucellosis, the purified
mAb 6C12 was labeled with phycoerythrin (PE) by PE/R-
Phycoerythrin Conjugation Kit according to the manufacturer’s
instructions (Abcam, Cambridge, United Kingdom). FITC-Anti-
CD14 antibody (M5E2 clone; BD, Bioscience, USA) was used
to recognize the lineage of mononuclear cells. PBMCs collected
from 28 brucellosis patients and 55 non-Brucella-infected blood
donors were stained for intracellular Brucellae by FACSCalibur
flow cytometer with FITC-Anti-CD14 antibody (M5E2) and PE-
6C12 specific to FCM Omp25 (Delaporte et al., 2008; Okumura
et al., 2015). Briefly, PBMCs were treated with 5 µl FITC-M5E2
for 30min at room temperature and cells were washed twice with
sample buffer [PBS containing 1% bovine serum albumin (BSA;
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3 April 2020 | Volume 10 | Article 145
Yang et al. Brucella Detection by mAbs to Omp25
Sigma-Aldrich, St Louis, Missouri, USA)]. After fixation and
permeabilization with Intracellular Fixation & Permeabilization
Buffer (eBioscience, California, USA), PBMCs were incubated
with PE-6C12 for 45min at 4◦C and washed three times.
Finally, 300 µl of resuspended PBMCs were tested by FCM.
All steps were performed in the dark. The data were analyzed
by FlowJo software version v10.0. The cutoff for non-Brucella-
infected PBMCs from healthy blood donors was established as
1% by FCM.
Statistical Analysis
Computer software (SPSS, Version 20.0, SPSS, Inc., Chicago, IL)
was used for statistical analysis. All experiments were repeated
at least three times independently. The results were presented as
the mean± SD.
RESULTS
Production and Identification of mAbs to
Brucella Omp25
Soluble rOmp25 was purified as an immunogen by Ni-NTA
Agarose column. The purity of rOmp25 was about 95% of total
proteins (Figure 1A). Five mAbs (2B10, 6C12, 8F3, 4A12, and
4F10) were selected for reacting with rOmp25 and NMPs of
B. melitensis by ELISA, respectively (Figure 1B). Western blot
analysis showed all fivemAbs were highly reactive with denatured
rOmp25, while among them three mAbs (6C12, 8F3, and 4A12)
strongly reacted with the denatured NMPs of B. melitensis and
two (2B10 and 4F10) reacted weakly (Figure 1C). In addition,
only mAb 6C12 reacted with intracellular Brucella Omp25
expressed in 293FT cells (Figure 1C and Table 1). No mAbs
reacted with other recombinant proteins of Brucella (Omp31,
BP26, Omp19, and Omp16).
Classification and Affinity Titration of
Brucella Omp25 mAbs
mAbs 2B10, 6C12, 8F3, 4A12, and 4F10 were identified as 2
IgG1, 2 IgG2a and 1 IgG2b, respectively (Table 1). Antibody
titers were determined by ELISA at value of 1 at OD450.
The titer of mAbs 6C12, 8F3, and 4A12 was measured
up to 1:200,000, 2B10 up to 1:50,000, and 4F10 up to
1:1,000, respectively (Figure 2A). Correspondingly, the optimum
working concentration of these five mAbs was 1.14µg/ml
(4F10), 0.042µg/ml (2B10), 0.037µg/ml (6C12), 0.019µg/ml
FIGURE 1 | Purification and identification of recombinant Omp25. (A) The purified rOMP25 was analyzed by SDS-PAGE. Lane 1, purified Omp25 with 25 kD
molecular weight; lane 2, cell lysate of pET30a-Omp25 transformed E. coli (DH5α) after IPTG induction; lane 3, cell lysate of pET30a-Omp25 transformed E. coli
before IPTG induction. (B) Reactivity of five mAbs with rOMP25 or NMP of B. melitensis (M5-90 strain) in ELISA. (C) Reactivity of five mAbs with the denatured
rOMP25 (1st panel) or NMP (2nd panel) of B. melitensis in WB. The third panel showed the denatured lentivirus expressed Omp25 in 293FT cells by WB. NC, negative
control (recombinant NS3 to HCV).
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4 April 2020 | Volume 10 | Article 145
Yang et al. Brucella Detection by mAbs to Omp25
TABLE 1 | Characterization of mAbs reactive to Brucella Omp25.
mAb Isotype Titers Relative
affinity
Omp25
WB
NMP
WB
LV
WB
Omp25
ELISA
NMP
ELISA
LV
IFS
B. m
ICS
Epitope
(aa)/peptide
2B10 IgG2a(K) 1:2 × 104 0.5–1.0 ++ – – 2.6 3.0 + – L(36–156)/P7
4A12 IgG1(K) 1:1 × 105 1.0–1.5 ++ ++ – 1.8 2.6 + + L(24–42)/P2
4F10 IgG2b(K) 1:1 × 103 0.5–1.0 ++ – – 2.4 2.7 + – L(24–42)/P2
6C12 IgG2a(K) 1:1 × 105 1.0–1.5 ++ ++ + 2.5 3.3 ++ + SC(24–213)
8F3 IgG1(K) 1:1 × 105 1.5–2.0 ++ + – 2.4 2.0 + + L(68–86)/P4
NMP, native outer membrane proteins extracts of B. melitensis (B. m); LV, Lentivirus LV-HAGE-Omp25 transduced 293T cells; The numbers indicate the OD450 value in ELISA; The
reactivity levels are indicated by ++ (strongly reactive), + (reactive), or – (non-reactive) by WB, IFS, and ICS; L, linear epitope; SC, semi-conformational epitope.
FIGURE 2 | Determination of mAb titer and affinity. (A) Titration of mAb by an indirect ELISA. The mAb was serially diluted in 1:3. The optimum working concentration
was determined for a midpoint of the steep portion of the curve. (B) The measurement of antibody relative affinity by thiocyanate elution assay. The affinity index was
estimated by the molarity of NH4SCN causing 50% reduction from initial absorbance in the elution curves. All experiments were carried out in triplicate and the results
were calculated from three independent experiments.
(8F3), and 0.01µg/ml (4A12), respectively. An appropriate
dilution of 1:2,700 for 2B10, 1:900 for 4F10, 1:8,100 for
6C12 and 8F3, and 1:2,700 for 4A12 was used as initial
concentration of mAb to determine its relative affinity. The
relative affinity of mAb was estimated by thiocyanate elution
assay, calculated at 50% reduction from initial antibody reactivity
reached by increasing molarity of NH4SCN in the elution
curves (Figure 2B). Relative affinity of mAbs was around 1.0
(Table 1), among them the affinity of 2B10 and 4F10 ranged
from 1.0 to 1.5, 4A12 and 6C12 from 1.0 to 1.5, and 8F3 from
1.5 to 2.0, respectively.
Reactivity of mAbs With Brucella Species
The ability of mAbs to Omp25 from different strains of
Brucella, the SSPs extracted from B. melitensis (M5-90), B.
abortus (S19, 104M, and 2308), and B. suis (S2) were tested
by ELISA and WB. mAbs 4A12, 6C12, and 8F3 reacted
with all three of Brucella species by ELISA (Figure 3A). The
reactivity of 4A12 and 6C12 reached a relatively higher level
than 8F3, but 2B10 and 4F10 reacted at low level or did
not react. Western blot analysis showed these mAbs had a
reaction pattern similar to ELISA (Figure 3B). Specifically,
mAb 6C12 presented two reactive bands with Brucella strains
2308 (B. abortus), S19 (B. abortus), S2 (B. suis), and M5-
90 (B. melitensis), corresponding to Omp25 (the lower) and
Omp25d (the upper), respectively. The other four mAbs
reacted only with Omp25 (Figure 3B). No mAbs reacted with
lysates of Yersinia enterocolitica O:9, Salmonella spp., and
Escherichia coli.
mAb Recognition for Omp25 Epitopes
In order to identify the Omp25 antigenic epitopes, all mAbs
were tested in ELISA with 10 peptides derived from the
213 amino acid (aa) sequence of B. melitensis Omp25.
Four mAbs (4A12, 8F3, 4F10, and 2B10) reacted with three
different peptides (Figure 4A) identified as recognition of linear
epitopes. mAb 6C12 did not react with any peptides but
with denatured native Omp25 (Figure 3), corresponding to the
recognition of a semi-conformational epitope (Table 1). The
amino acid sequences of the three linear epitopes of Omp25
are presented in Figure 4B (19–20 mers peptides P2, P4,
and P7).
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FIGURE 3 | Detection of Brucella strains by mAbs to Omp25 in ELISA and WB. (A) The SSPs of M5-90, S19, 104M, 2308 and S2 strains were detected by an
indirect ELISA. (B)Western blot analysis for identifying Brucella strains and non-Brucella stain with mAbs to Omp25. Brucella 2308 is a wild strain of B. abortus, 104M
and S19 are vaccine strains of B. abortus, and S2 is a vaccine strain of B. suis, M5-90 is a vaccine strains of B. melitensis, respectively. E. coli (ATCC 23922) is used
as a negative control.
FIGURE 4 | Epitope mapping of Omp25. (A) mAb reacted with peptides derived from Omp25 in ELISA. (B) mAb recognized linear epitopes within Omp25. Aa
position is indicated at the beginning and the end of peptide sequence. mAb ID is indicated under the reactive peptide sequence. (C) Detection of Brucellae with
cross-matching mAbs. The SSPs from B. abortus (S19, 104M, 2308), B. suis (S2) and B. menlitensis (M5-90) were used as antigens for cross-matching the mAb pair
in DAS-ELISA. The capture mAb was used to coat microplates for Omp25 capture, and as detection mAb conjugated with HRP for detecting the captured Omp25
from various Brucella strains. E. coli was used as a negative control.
Detection of BrucellaeWith
Cross-Matching mAbs in ELISA
Five mAbs were tested for reactivity with Omp25 by cross-
matching pairs with capture and detection antibodies by
DAS-ELISA. Five pairs of mAbs (4A12/6C12-HRP, 4A12/8F3-
HRP, 6C12/8F3-HRP, 8F3/4A12-HRP, and 8F3/6C12-HRP)
reacted with rOmp25 (Table S2). These five pairs were tested
for reactivity with the SSPs of 2308, 104M, S19, S2, and
M5-90 strains from B. melitensis, B. abortus, or B. suis.
Two mAb pairs, 8F3/6C12-HRP and 8F3/4A12-HRP, were
found the be more reactive for detection of various Brucella
species (Figure 4C).
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FIGURE 5 | Detection of intracellular Brucellae-infected PBMCs from brucellosis patients by FCM. Monocytes were sorted by staining with mAb to CD14 (FITC-M5E2),
and were further calculated by mAb to Brucella Omp25 (PE-6C12) as a percentage of total monocytes. (A) Detection of PBMCs from Healthy blood donors who were
used as negative control. (B) Detection of PBMCs from brucellosis patients who were confirmed positive by SAT and PCR at administration to hospital.
Detection of Brucellae by Immunostaining
With Omp25 mAbs
To determine the ability of Omp25 mAbs to detect intracellular
Brucellae or intact Brucella strains by microscopy, infected
cells or intact bacteria were stained by IFS or ICS,
respectively. mAbs 6C12, 2B10, and 4F10 showed a strong
fluorescent reactivity with the lentivirus-Omp25 transduced
293FT cells by IFS (Figure S1A). In addition, by IFS with
mAb 6C12 from two patients with brucellosis, visible
fluorescent intracellular Brucellae infected PBMCs were
observed, but not seen with controls from healthy blood
donors (Figure S1B).
By ICS, the cultured Brucella could be seen by microscopy
after staining with HRP-conjugated 6C12, 8F3, or 4A12 on a glass
slide (Figure S2). The overall results are presented in Table 1.
Clinical Detection of Brucellae-Infected
PBMCs From Brucellosis Patients by FCM
On the basis of the above analysis, mAb 6C12 was considered
the most functional antibody for Brucella detection. Hence, mAb
6C12 was selected for labeling with PE to detect intracellular
Brucellae-infected PBMCs by FCM (Figure 5). The mononuclear
cells were sorted from freshly isolated PBMCs by FITC-Anti-
CD14 antibody (M5E2), and the ratio of Brucella-infected
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monocytes was calculated by staining with PE-6C12. Stained
monocytes from healthy blood donor controls over brucellosis
patients were stratified as the cutoff or threshold between two
levels of intracellular Brucellae: <1.0%, indicating a lower level
or negative intracellular Brucellae-infected cells (Figure 5A),
and ≥1.0%, indicating a higher level of intracellular Brucellae-
infected cells (Figure 5B). A total of 28 brucellosis patients
and 20 blood donors were tested by FCM with both mAbs
M5E2 and 6C12, showing that 46.4% (13/28) of brucellosis
patients but none of blood donors carried intra-PBMCs Brucellae
(≥1.0%) (Table 2). Only one patient (No. 8) had 1.13% of
stained monocytes with unclear boundary by FCM. These results
suggested that FCM with mAb 6C12 might be a practical assay
to determine the frequency of intracellular Brucellae-infected
PBMCs in individual brucellosis patients with clinical diagnosis.
DISCUSSION
Several early studies focused on the immunogenicity and
protective activity of Brucella Omp25 (Bowden et al., 1998).
In this study, three non-overlapping linear epitopes (P2, P4,
and P7) were recognized by mAbs 4A12 and 4F10, 8F3, and
2B10, respectively (Figure 4B). Previously mAb A59/05F01/C09
was reported to recognize a liner epitope of Omp25 (aa 24-43)
(Salhi et al., 2003), which overlaps with the epitope P2 (aa24-42)
recognized by mAbs 4A12 and 4F10 in this study. P1 peptide
(aa1-30) has seven amino acids (24-ADAIQEQ-30) overlapping
with P2 peptide (Table S1) but does not react with these mAbs,
suggesting that mAbs 4A12 and 4F10 likely recognize the linear
epitope PPVPAPVEVAPQ (aa 31-42) within Omp25. Another
mAb A76/02C12/C11 to Omp25 was reported to strongly bind
to rough Brucella isolates except B. ovis tested with a latex co-
agglutination assay (Bowden et al., 1997), but the epitope was
not clearly defined. In addition to the three different linear
epitopes (P2, P4, and P7) revealed by mAbs 4A12 and 4F10, 8F3,
and 2B10, a semi-conformational epitope within the denatured
native Brucella Omp25 was identified by mAb 6C12 recognition.
Interestingly, mAb 6C12 recognized two bands of 25 kD and 26
kD proteins from Brucella strains in WB (Figure 3B). The larger
band (26 kD) was designated as Omp25d as previously described
(Salhi et al., 2003), while the other four mAbs reacted only with
the linear epitopes of 25 kD protein (Omp25). This might explain
that 6C12 had better binding capacity in FCM than other mAbs
for detecting Brucellae of PBMCs in comparison with mAb 5H3
to Omp31 or 5A5 to BP26 (Yang et al., 2019). These Omp25
mAbs had no cross-reactivity with Yersinia enterocolitica O:9,
Salmonella spp., and Escherichia coli reported previously (Muñoz
et al., 2015). However, previous studies found the high serological
cross-reactivity between Brucella and other Alphaproteobacteria
such as Ochrobactrum and Sinorhizobium (Cloeckaert et al.,
1999; Velasco et al., 2000; Delpino et al., 2004). By aligning
Brucella Omp25 aa sequence with Ochrobactrum anthropi and
Rhizobiales 63-22 strains, the high homologous sequences are
observed including the linear epitopes (P2, P4, and P7) within
Brucella Omp25 recognized by mAbs 4A12/4F10, 8F3, and 2B10
TABLE 2 | Characterization of blood samples and detection results of
Brucellae-infected PBMCs by FCM with mAb PE-6C12.
Number Sample source Status FCM (%) PCR SAT
1 Brucellosis patient Acute 0.99 + 1:200
2 Brucellosis patient Chronic 0.39 + 1:100
3 Brucellosis patient Acute 1.59 + 1:100
4 Brucellosis patient Chronic 0.57 + 1:100
5 Brucellosis patient Chronic 0.97 + 1:400
6 Brucellosis patient Chronic 0.61 + 1:100
7 Brucellosis patient Acute 1.26 + 1:800
8 Brucellosis patient Acute 1.13 (unclear
boundary)
+ 1:400
9 Brucellosis patient Acute 2.04 + 1:50
10 Brucellosis patient Acute 0.73 + 1:100
11 Brucellosis patient Acute 0.79 + 1:100
12 Brucellosis patient Chronic 2.41 + 1:50
13 Brucellosis patient Acute 1.19 + 1:800
14 Brucellosis patient Acute 0.69 + 1:400
15 Brucellosis patient Chronic 0.75 + 1:100
16 Brucellosis patient Chronic 0.8 + 1:200
17 Brucellosis patient Acute 0.79 + 1:100
18 Brucellosis patient Chronic 1.38 + 1:100
19 Brucellosis patient Chronic 0.65 + 1:100
20 Brucellosis patient Chronic 1.37 + 1:50
21 Brucellosis patient Acute 1.18 + 1:100
22 Brucellosis patient Acute 1.15 + 1:400
23 Brucellosis patient Acute 1.97 + 1:200
24 Brucellosis patient Chronic 2.43 + 1:50
25 Brucellosis patient Chronic 3.12 + 1:100
26 Brucellosis patient Chronic 4.14 + 1:50
27 Brucellosis patient Acute 0.43 + 1:100
28 Brucellosis patient Chronic 0.46 + 1:50
29 Blood donor 0.49 – –
30 Blood donor 0.31 – –
31 Blood donor 0.18 – –
32 Blood donor 0.41 – –
33 Blood donor 0.1 – –
34 Blood donor 0.4 – –
35 Blood donor 0.15 – –
36 Blood donor 0.22 – –
37 Blood donor 0.28 – –
38 Blood donor 0.25 – –
39 Blood donor 0.3 – –
40 Blood donor 0.58 – –
41 Blood donor 0.23 – –
42 Blood donor 0.37 – –
43 Blood donor 0.47 – –
44 Blood donor 0.29 – –
45 Blood donor 0.35 – –
46 Blood donor 0.52 – –
47 Blood donor 0.46 – –
48 Blood donor 0.24 – –
FCM, flow cytometry; SAT, standard agglutination test.
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(Figure S3), which indicate the cross-reactivity of these mAbs
may exist in other Alphaproteobacteria.
B. melitensis, B. abortus, and B. suis are three major
pathogenic strains for human brucellosis transmitted from
infected sheep and goats, cattle, or pigs (Chen et al., 2014;
Ducrotoy et al., 2018). Among five mAbs, 8F3, 4A12, and
6C12 had higher relative affinity (>1) reacted with Omp25
of five strains (M5-90, S19, 104M, 2308, and S2) from three
Brucella in various immunoassays. mAb 8F3 presented a
strong capacity as a capture antibody (Figure 4C), while
6C12 and 4A12 appeared to be the best detection antibody
when conjugated with HRP or fluorescein (Figure 4C,
Figures S1, S2). The best-matched antibody pairs were
8F3/6C12-HRP and 8F3/4A12-HRP for detection of Brucellae
in DAS-ELISA, while mAb 6C12 was the most suitable for
detection of intracellular Brucellae in PBMCs from patients by
FCM (Figure 5).
Currently, there is no an optimal immunoassay for detecting
intracellular Brucellae in terms of counting the infected
monocytes for evaluation of anti-Brucella efficacy in clinical
treatment of brucellosis. Conventional method of blood culture
requires a biosafety level 3 laboratory (BSL-3) and takes 1–
2 weeks (Pappas et al., 2006). In this study, we sought to
develop an Omp25 mAb-based FCM assay to detect intracellular
Brucellae-infected PBMCs from brucellosis patients, whichmight
be helpful for evaluating therapeutic efficacy by determining
the percentage of Brucella-infected monocytes before or after
treatment of individual patients with brucellosis. By analyzing
28 patients with brucellosis, who were found positive upon
admission to hospital by SAT and PCR, eight out of 28
(28.6%) and five out of 28 (17.8%) brucellosis patients had
more than 1 or 2% intracellular Brucellae infected PBMCs,
respectively. Overall, 46.4% (13 out of 28) patients carried
a higher level (>1%) of intracellular Brucellae monocytes
and 53.6% (15 out of 28) patients had a lower level (<1%)
or no detectable intracellular Brucellae monocytes (Table 2).
The ratios of mAb 6C12-stained monocytes from PBMCs
were consistent with the amounts of intracellular Brucellae in
brucellosis patients. In our previous study, we utilized IFS
for detecting Brucella-infected PBMCs stained with Omp31
mAbs (Yang et al., 2019) and found 50–70% positive PBMCs
in patients receiving zero to three treatment courses of anti-
Brucella drugs. IFS is a qualitative test unsuitable to quantify
the number of Brucella-infected cells in a patient’s PBMCs.
The selected mAb 6C12 has been shown effective for detection
of intracellular Brucella by IFS (Figure S1). However, the
established FCM with mAb 6C12 specific to Omp25 has an
advantage over IFS for counting the frequency of intracellular
Brucellae-infected monocytes and might be a potential assay
for evaluation of therapeutic efficacy of brucellosis patients in
clinical practice.
In conclusion, mAbs 8F3 was suitable as an immobilized
capture antibody, and 6C12 or 4A12 was suitable as a conjugated
detection antibody. These mAbs specific to Brucella Omp25
appear precious reagents in various immunoassays, such as
WB, ELISA, ICS, IFS, and FCM assays for detection of
different Brucella species in the diagnosis of brucellosis or
evaluation of therapeutic efficacy of anti-Brucella treatment in
clinical practice.
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